Source-grounded facts extracted from COGNITION THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
COGNITION THERAPEUTICS INC reported the first quarter ended March 31, 2026 results: net income $4.6 million, EPS $(0.05) per basic and diluted share.
“expenses was driven primarily by lower stock compensation, compensation and professional fees. Cognition Therapeutics, Inc. www.cogrx.com The Company reported a net loss of $4.6 million, or $(0.05) per basic and diluted share for the first quarter ended March 31, 2026, compared to a net loss of $8.5 million, or $(0.14) per basic and diluted share for the same”
Earnings Releases
COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.
“$12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference”
Earnings Releases
COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.
“The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024”
Earnings Releases
COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.
“The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023”
Material Agreements
COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2024-03-11).
“On March 11, 2024, Cognition Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell to the Underwriter, in a public offering (the “Offering”), 6,571,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $1.75 per share (the “Offering Price”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.